BioAge Labs, Inc (BIOA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioAge Labs, Inc (BIOA) has a cash flow conversion efficiency ratio of -0.058x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.04 Million) by net assets ($277.46 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BIOA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
BioAge Labs, Inc - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how BioAge Labs, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioAge Labs, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioAge Labs, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
D-MARKET E.S.+T.SP.ADR/1B
F:8WZ
|
2.184x |
|
Suning Universal Co Ltd
SHE:000718
|
0.008x |
|
Shenzhen Sunxing Light Alloys
SHG:603978
|
-0.075x |
|
Barclays PLC
LSE:BARC
|
0.243x |
|
Revolve Group LLC
NYSE:RVLV
|
0.024x |
|
Sheela Foam Limited
NSE:SFL
|
0.038x |
|
Beijing Dataway Horizon Co. Ltd
SHE:301169
|
N/A |
|
Sats ASA
OL:SATS
|
0.451x |
Annual Cash Flow Conversion Efficiency for BioAge Labs, Inc (2013–2024)
The table below shows the annual cash flow conversion efficiency of BioAge Labs, Inc from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see BioAge Labs, Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $323.13 Million | $-51.52 Million | -0.159x | -174.00% |
| 2023-12-31 | $-173.40 Million | $-37.36 Million | 0.215x | -32.97% |
| 2022-12-31 | $-112.56 Million | $-36.18 Million | 0.321x | +123.58% |
| 2017-12-31 | $21.85 Million | $-29.79 Million | -1.363x | -75.73% |
| 2016-12-31 | $48.49 Million | $-37.62 Million | -0.776x | -11.68% |
| 2015-12-31 | $46.36 Million | $-32.20 Million | -0.695x | -77.97% |
| 2014-12-31 | $57.53 Million | $-22.45 Million | -0.390x | +7.82% |
| 2013-12-31 | $65.01 Million | $-27.52 Million | -0.423x | -- |
About BioAge Labs, Inc
BioAge Labs, Inc. is a biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. It also provides azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment o… Read more